Latissebimatoprost
According to the FDA label: LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. ( 1 )
11,096 adverse event reports submitted to the FDA (2004–2026)
Top Reported Adverse Events
The most frequently reported events in association with Latisse in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Drug Ineffective 2,406 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →- Ocular Hyperaemia 1,476 reports
- Madarosis 1,362 reports
Eye Irritation 1,016 reports
Discomfort, redness, or itching of the eye.
Full definition in the glossary →- Eye Pruritus 959 reports
- Erythema Of Eyelid 899 reports
- Eyelids Pruritus 482 reports
- Eye Swelling 477 reports
Wrong Technique in Product Usage Process 454 reports
A report that the medication was used or administered with the wrong technique, such as an incorrect injection or inhaler method. This is a usage category, not a sign of a problem with the drug itself.
Full definition in the glossary →- Wrong Technique In Drug Usage Process 384 reports
- Eyelid Oedema 375 reports
Inappropriate Schedule of Drug Administration 373 reports
A report that a medication was taken on the wrong schedule, such as too often or at the wrong time. This is a usage category, the same idea as inappropriate schedule of product administration.
Full definition in the glossary →Dry Eye 364 reports
A lack of enough tears to keep the eye comfortable, causing dryness or irritation.
Full definition in the glossary →- Skin Hyperpigmentation 362 reports
- Eyelid Irritation 335 reports
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 9,482 |
| Male | 827 |
| Unknown | 10 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 80 |
| 18-34 | 411 |
| 35-49 | 1,161 |
| 50-64 | 1,847 |
| 65-74 | 1,061 |
| 75+ | 839 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Latisse. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 9,349 |
| Other Serious | 1,192 |
| Hospitalization | 693 |
| Death | 123 |
| Life-Threatening | 120 |
| Disability | 98 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Latisse. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 397 |
| 2010 | 1,527 |
| 2011 | 886 |
| 2012 | 513 |
| 2013 | 66 |
| 2014 | 95 |
| 2015 | 1,039 |
| 2016 | 1,023 |
| 2017 | 1,070 |
| 2018 | 834 |
| 2019 | 698 |
| 2020 | 635 |
| 2021 | 505 |
| 2022 | 400 |
| 2023 | 596 |
| 2024 | 391 |
| 2025 | 301 |
| 2026 (partial) | 65 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Latisse
In FDA adverse event reports that mention Latisse, these medications appeared most often in the same report.
- Omeprazole (316 reports)
- Aspirin (303 reports)
- Levothyroxine (290 reports)
- Acetaminophen (268 reports)
- Brimonidine (264 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026